Pulnovo Medical Announces Appointment of Renowned Cardiovascular Expert Dr. Krishna Sudhir to Scientific Advisory Board

In June 2022, Pama Medical announced that Dr. Krishna Sudhir had officially joined its Scientific Advisory Board. As a Chinese innovator originating in the cardiopulmonary field and dedicated to addressing broader unmet clinical needs, Pama Medical has long been committed to scientific exploration of breakthrough technologies and commercial expansion with a global perspective. The company strives to build an OTM (From Operating Table to Market) innovation platform driven by clinical value, acting to enhance patients’ resilience. Dr. Krishna Sudhir will provide scientific guidance for Pama Medical’s technology platform and R&D pipeline strategy, collaboratively promoting the incubation of innovative technologies and the internationalization of its products, thereby helping Chinese original technologies reach the global market.

Dr. Krishna Sudhir is a distinguished expert in the field of cardiovascular medicine, currently serving asMedical Advisor Professor, Stanford University Cardiovascular Technology Center. He previously served asAbbott Cardiovascular（Abbott Vascular）Global Vice President, Medical Affairs, he possesses extensive international leadership experience in technological R&D, medical exploration, and commercial strategic thinking within the medical field. Previously, he successively joinedUniversity of California, San Francisco; Alfred Heart CenterandBeck Heart and Diabetes Institute, specializing in research on heart diseases; subsequentlyat multiple pharmaceutical companies, including Pharmacyclics, Millennium, and diaDexusResponsible for clinical research and medical affairs; later joinedJohnson & Johnson(Johnson & Johnson), serving asExecutive Director of Macroflux Internal Venture; Dr. Krishna Sudhir earned his Doctor of Medicine degree from Madras Medical College and his Doctor of Philosophy degree from Monash University. His outstanding academic achievements have garnered him numerous honors, and he holds multiple professional distinctions, including Fellow of the Royal Australasian College of Physicians, Member of the American College of Cardiology, and Member of the Society for Cardiovascular Angiography and Interventions.

Dr. Krishna Sudhir stated:It is a great honor for me to join Pama Medical as a member of the Scientific Advisory Board (SAB), contributing to its technological R&D, commercial strategy, and scientific innovation. Pama Medical implements full-chain management spanning “medicine, engineering, research, production, and commerce.” Its pioneering explorations in the medical field will deliver innovative therapeutic solutions to address long-standing unmet clinical needs worldwide. For patients with limited treatment options, these innovative therapies will undoubtedly enhance their health resilience. It is a privilege to collaborate with the Pama Medical team to develop and explore new treatments that meet patients’ urgent needs, and to jointly create differentiated, innovative medical technologies. There is no nobler aspiration than this goal.

Pamu Medical stated:Pamu Medical sincerely welcomes Dr. Krishna Sudhir to its Scientific Advisory Board. As a distinguished scientist and leader in the field, Dr. Sudhir’s strong scientific foundation, strategic thinking, and business acumen will significantly enhance Pamu Medical’s innovation capabilities. His expertise will further strengthen the strategic layout of our product pipeline and foster international collaborations, propelling Pamu Medical to new heights.

Pamu Medical, founded in 2013 with a focus on cardiopulmonary care, is dedicated to addressing unmet clinical needs. By consistently advancing scientific exploration of breakthrough technologies and pursuing commercialization with a global perspective, Pamu Medical strives to build an OTM (From Operating Table to Market) innovation platform driven by clinical value, acting to restore patients’ resilience for life.

Multiple products developed by Pamu Medical, led by its high-frequency ablation system, are international firsts. The company has successfully secured more than 50 invention patents and methodological protections both domestically and internationally, gained entry into the National Medical Products Administration (NMPA) Green Channel for Innovative Medical Devices, and obtained CE quality system certification. In February 2021, Pamu Medical’s originally developed radiofrequency ablation catheter for pulmonary hypertension was granted FDA Breakthrough Device Designation in just 16 days, making it the first Chinese company in this field to receive such designation. In August of the same year, the company secured a new round of financing exceeding RMB 100 million from investors including OrbiMed, Qianji Capital, Lilly Asia Ventures, and Gaorong Capital.

Driven by a commitment to innovation and the craftsmanship of enhancing patients’ health resilience, PAM Medical has remained dedicated from the operating room to the marketplace to delivering breakthrough therapies anchored in clinical value. Emerging as a dark horse, it has rapidly taken the lead in interventional therapies for pulmonary arterial hypertension and will continue to uphold its foundational principles, leveraging relentless R&D strength to usher patients into a new era.